Sugi Predict

Sugi Predict / Targets / LYN

LYN

Tyrosine-protein kinase Lyn · P07948 · LYN on Sugi Atlas →

158,979 patent compounds predicted against LYN, 129,713 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Linifanib Linifanib (SCHEMBL93804) 1.00 7/20
SCHEMBL95142 SCHEMBL95142 1.00 5/20
SCHEMBL94964 SCHEMBL94964 0.79 5/20
SCHEMBL90887 SCHEMBL90887 0.49 5/20
SCHEMBL90935 SCHEMBL90935 0.49 5/20
SCHEMBL60289 SCHEMBL60289 0.48 5/20
SCHEMBL58735 SCHEMBL58735 0.47 5/20
Nilotinib Nilotinib (SCHEMBL7901) 1.00 4/20
SCHEMBL94862 SCHEMBL94862 1.00 4/20
SCHEMBL58313 SCHEMBL58313 0.59 4/20
SCHEMBL58543 SCHEMBL58543 0.57 4/20
SCHEMBL60464 SCHEMBL60464 0.57 4/20
SCHEMBL58550 SCHEMBL58550 0.55 4/20
SCHEMBL58416 SCHEMBL58416 0.50 4/20
SCHEMBL59547 SCHEMBL59547 0.49 4/20
SCHEMBL66159 SCHEMBL66159 0.49 4/20
SCHEMBL60366 SCHEMBL60366 0.45 4/20
SCHEMBL58496 SCHEMBL58496 0.44 4/20
SCHEMBL41486 SCHEMBL41486 0.44 4/20
SCHEMBL58420 SCHEMBL58420 0.43 4/20

Clinical trials — most relevant to LYN by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment PHASE3UNKNOWN
Masitinib in the Treatment of Patients With Severe Uncontrolled Asthma and Elevated Eosinophil Levels PHASE3COMPLETED
Combination of Ibrutinib and As2O3 in the Treatment of CLL PHASE3UNKNOWN
A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple Myeloma PHASE2COMPLETED
Phase II Dasatinib Study in Advanced Breast Cancer PHASE2COMPLETED
Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia PHASE1/PHASE2COMPLETED
Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma PHASE2COMPLETED
Study on Treatment Outcome Patterns for Patients With CLL After Discontinuation of BTK Inhibitors PHASE2NOT_YET_RECRUITING
Proof of Concept Study of Rilzabrutinib in Adult Participants With Moderate-to-severe Asthma PHASE2COMPLETED
Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell Lymphoma PHASE2UNKNOWN
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma PHASE2COMPLETED
An Adaptive Design Study of MTX228 PHASE2RECRUITING
Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL PHASE2RECRUITING
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis. PHASE2COMPLETED
PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma PHASE2ACTIVE_NOT_RECRUITING
Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission PHASE2NOT_YET_RECRUITING
Fostamatinib for Hospitalized Adults With COVID-19 PHASE2COMPLETED
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies PHASE1/PHASE2RECRUITING
Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL PHASE2ACTIVE_NOT_RECRUITING
Study of Bafetinib as Treatment for Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) PHASE2COMPLETED
A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia PHASE1COMPLETED
A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) PHASE1ACTIVE_NOT_RECRUITING
Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation) PHASE1COMPLETED
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers PHASE1ACTIVE_NOT_RECRUITING
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia PHASE1COMPLETED
Effect of Imatinib on Suppression of Malaria Parasites in Patients With Uncomplicated Plasmodium Falciparum Malaria PHASE1COMPLETED
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) PHASE1COMPLETED
Pathogenesis of BTK-mediated Hyper-Inflammatory Responses in COVID-19 (RESPOND) nanWITHDRAWN
Ibrutinib Adapted to Response in Patients With CLL nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a LYN binder may also engage these)

ProteinNameSimilarity
P25911 — 1.000 P25911 →
Q07014 — 1.000 Q07014 →
P50545 — 1.000 P50545 →
P10936 — 1.000 P10936 →
HCK Tyrosine-protein kinase HCK 1.000 landscape →
FYN Tyrosine-protein kinase Fyn 1.000 landscape →
Q62844 — 0.999 Q62844 →
P06240 — 0.999 P06240 →
Q95M30 — 0.999 Q95M30 →
Q5PXS1 — 0.998 Q5PXS1 →
P00527 — 0.998 P00527 →
Q6EWH2 — 0.997 Q6EWH2 →
A1A5H8 — 0.997 A1A5H8 →
Q01621 — 0.997 Q01621 →
YES1 Tyrosine-protein kinase Yes 0.997 landscape →
F1LM93 — 0.997 F1LM93 →
A1Y2K1 — 0.996 A1Y2K1 →
Q9V9J3 — 0.996 Q9V9J3 →
P42683 — 0.996 P42683 →
P39688 — 0.995 P39688 →
P27447 — 0.995 P27447 →
P09324 — 0.995 P09324 →
Q28923 — 0.995 Q28923 →
P08103 — 0.994 P08103 →
Q05876 — 0.993 Q05876 →
Q04736 — 0.993 Q04736 →
Q02977 — 0.993 Q02977 →
FGR Tyrosine-protein kinase Fgr 0.993 landscape →
P63185 — 0.992 P63185 →
LCK Tyrosine-protein kinase Lck 0.992 landscape →